Arrowhead, Amgen license and collaboration agreement closed

American Pharmacy News Reports | Nov 23, 2016
The agreement failed because of the early termination waiting period.
The agreement failed because of the early termination waiting period. | File image
Arrowhead Pharmaceuticals has closed the license and collaboration agreement with Amgen regarding the RNAi ARC-LPA program.
The agreement fell through because of the early termination of the waiting period according to the Hart-Scott Rodino Antitrust Improvements Act of 1976.
More News

Those with preexisting health conditions may experience a different immune response to the COVID-19 vaccination.

People CDC releases COVID-19 guidance for those with health conditions Jan 10, 2021

Novavax is the latest COVID-19 vaccine to enter Phase III clinical trials.

Innovation Fifth vaccine set to enter Phase III clinical trials Jan 3, 2021

Regulatory CENTENE: Completes Acquisition of PANTHERx Rare Pharmacy (PANTHERx) Dec 31, 2020

Industry NHA: Creates Partnership, Path for Accredited Immunization Training for Pharmacy Technicians Ahead of New Vaccines Dec 31, 2020

Industry TRANQUILMONEY: Releases PharmTracker for Independent Pharmacies, Small and Medium Pharmacy Chains Dec 26, 2020

Industry MITSUBISHI TANABE PHARMA AMERICA: Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS Dec 22, 2020

Trending

Those with preexisting health conditions may experience a different immune response to the COVID-19 vaccination.

CDC releases COVID-19 guidance for those with health conditions